Cassava Sciences Inc vs Rivian Automotive, Inc. — how do they compare? Cassava Sciences Inc trades at $0.93 (market cap $47.75M), while Rivian Automotive, Inc. trades at $15.92 (market cap $23.69B). The key difference: Rivian Automotive, Inc. is far larger — about 496.1× Cassava Sciences Inc's market cap, and Rivian Automotive, Inc. is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | RIVN | |
|---|---|---|
Market Cap | $47.75M | $23.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $22.45 |
52-Week Low | $0.87 | $11.97 |
Enterprise Value | -$34.93M | $23.73B |
Signals from Pluang's Aura AI — not financial advice
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
Rivian (RIVN) trades at $16.015, down 2.29% today, with a bullish technical signal from moving averages but neutral oscillators. The company shows improving fundamentals with revenue growth from $5.0B in 2024 to $5.4B in 2025, though net losses persist at -$3.65B. Recent R2 vehicle launches and raised 2026 delivery guidance to 65,000-70,000 vehicles indicate operational progress. Analyst consensus is mixed with 48% buy ratings and a $18.70 price target, suggesting 17% upside potential from current levels.
Rivian presents a high-risk growth opportunity with significant cash burn ($1.72B net outflow in 2025) but improving margin trends. The R2 ramp-up and Uber partnership offer catalysts, though execution risks and EV market competition remain concerns. With negative profitability metrics and substantial debt, the stock suits investors comfortable with early-stage company volatility seeking EV market exposure.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →